Skip to main content

Is My Product Recalled?

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Scan How It Works Saved Get Alerts

Menu

Search All Recalls Latest Recalls Scan Barcode Get Alerts

Categories

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Resources

How Recalls Work FAQ Recall Classifications Statistics & Trends About

Your Recalls

Loading...

Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

Search Product Recalls

Try:····

Filters

Category

All Categories Food Medication Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Time Period

All Time Last 30 Days Last 90 Days Last Year

State

Severity

All Severities Class I (High Risk)Class II (Moderate)Class III (Low)

Source

All Sources FDA CPSC USDA NHTSA

Status

Include terminated recalls

Clear all filters

Showing 6121–6140 of 15081 results

Sort:

Newest first Oldest first

Telmisartan Hydrochlorothiazide Tablets (Macleods) – Blend Uniformity Issue (2019)

Failed Content Uniformity Specifications: The product is out of specification for blend uniformity.

Class IIModerate

FDAFeb 25, 2019Nationwide• Macleods Pharma Usa Inc

Tamsulosin Hydrochloride Capsules (Ascend) – Dissolution Failure (2019)

Failed Dissolution Specifications: High Out-of-Specification dissolution results were observed during stability testing.

Class IIModerate

FDAFeb 22, 2019Nationwide• Ascend Laboratories LLC

Gentamicin Sulfate Ophthalmic Solution (Akorn) – Impurity Levels (2019)

Failed Impurities/Degradation Specifications: High Out-of-Specification (OOS) results for Individual and Total Impurities that have been identified at the 18 months stability testing time point.

Class IIModerate

FDAFeb 22, 2019Nationwide• Akorn, Inc.

Golean DETOX Capsules (Golean Detox) – Undeclared Ingredients (2019)

Undeclared Allergen

Marketed Without an Approved NDA/ANDA: FDA analysis found product to contain undeclared sibutramine and phenolphthalein. Sibutramine is an appetite suppressant that was withdrawn from the US market due to safety concerns. Phenolphthalein was once an ingredient used in over-the-counter laxatives, but because of concerns of carcinogenicity is not currently approved for marketing in the US. The presence of sibutramine and phenolphthalein in this product renders it an unapproved drug for which the safety and efficacy has not been established and, therefore, subject to recall.

FDAFeb 22, 2019Nationwide• Golean Detox US

PGE1 Injectable (Health Solutions) – Insanitary Conditions (2019)

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Class IIModerate

FDAFeb 21, 2019IN, OR• Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy

Sodium Chloride Eye Drops (Health Solutions) – Insanitary Conditions (2019)

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Class IIModerate

FDAFeb 21, 2019IN, OR• Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy

Papaverine Injectable (Health Solutions) – Insanitary Conditions (2019)

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Class IIModerate

FDAFeb 21, 2019IN, OR• Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy

Oxybutynin Chloride Tablets (Lannett) – Dissolution Failure (2019)

Failed Dissolution Specifications

FDAFeb 21, 2019Nationwide• Lannett Company Inc.

Papaverine Injectable (Health Solutions) – Insanitary Conditions (2019)

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Class IIModerate

FDAFeb 21, 2019IN, OR• Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy

Hydroxyprogesterone Injectable (Health Solutions) – Insanitary Conditions (2019)

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Class IIModerate

FDAFeb 21, 2019IN, OR• Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy

Acetyl-L-Cysteine Eye Drops (Health Solutions) – Insanitary Conditions (2019)

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Class IIModerate

FDAFeb 21, 2019IN, OR• Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy

Papaverine Injectable (Health Solutions) – Insanitary Conditions (2019)

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Class IIModerate

FDAFeb 21, 2019IN, OR• Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy

Dexamethasone Eye Drops (Health Solutions) – Insanitary Conditions (2019)

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Class IIModerate

FDAFeb 21, 2019IN, OR• Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy

PGE1-Lidocaine Injectable (Health Solutions) – Insanitary Conditions (2019)

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Class IIModerate

FDAFeb 21, 2019IN, OR• Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy

Losartan Potassium Tablets (Macleods) – NDEA Contamination (2019)

CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.

Class IIModerate

FDAFeb 21, 2019FL, NJ, NY• Macleods Pharma Usa Inc

Hydrogen Peroxide Solution (Vi-Jon) – IPA Contamination (2019)

Cross Contamination: Presence of IPA in finished product.

Class IIModerate

FDAFeb 20, 2019IN, OH• Vi-Jon, Inc.

Temozolomide Capsules (Amerigen) – Failed Dissolution (2019)

Failed dissolution specifications

FDAFeb 19, 2019Nationwide• Amerigen Pharmaceuticals Inc.

Lovastatin Tablets USP (American Health Packaging) – CGMP Deviations (2019)

CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results.

FDAFeb 19, 2019Nationwide• American Health Packaging

Cefuroxime Injection (Leiter's) – Incorrect Formulation (2019)

Incorrect Product Formulation; compounded sterile drug reconstituted using sterile water instead of sterile 0.9% Sodium Chloride.

Class IIModerate

FDAFeb 19, 2019AZ, CA, MI +1 more• Leiter's Enterprises, Inc.

Etomidate Injection (Heritage) – Subpotent Drug (2019)

Subpotent Drug.

Class IIModerate

FDAFeb 15, 2019Nationwide• Heritage Pharmaceuticals, Inc.

1...305 306307308 309...755

Page 307 of 755Next